Literature DB >> 9748528

Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain.

A Rassoulpour1, H Q Wu, B Poeggeler, R Schwarcz.   

Abstract

Tissue levels of the endogenous excitatory amino acid receptor antagonist kynurenic acid (KYNA) and of its bioprecursor L-kynurenine were measured in rats of different ages after d-amphetamine administration. In adult animals, extracellular KYNA concentrations were also determined in vivo by hippocampal microdialysis. In the adult brain, d-amphetamine caused a transient, dose-dependent decrease in tissue content and extracellular levels of KYNA, reaching a nadir of approximately 70% of control values after 1 h at 5 mg/kg. Quantitatively similar decrements were observed in four different brain regions. Seven, 14 and 28-day-old pups were particularly sensitive to the drug, showing a reduction in forebrain KYNA levels to 25%, 40% and 35% of control values, respectively, 1 h after the administration of 5 mg/kg d-amphetamine. Notably, no changes in brain L-kynurenine levels and in liver L-kynurenine and KYNA concentrations were found after d-amphetamine administration. Thus, endogenous monoamines released by d-amphetamine may interfere with the transamination of L-kynurenine to KYNA specifically in the brain. These results suggest that d-amphetamine increases excitatory amino acid receptor function temporarily by reducing the levels of endogenous KYNA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748528     DOI: 10.1016/s0006-8993(98)00577-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

2.  Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease.

Authors:  Kuo-Hsuan Chang; Mei-Ling Cheng; Hsiang-Yu Tang; Cheng-Yu Huang; Yih-Ru Wu; Chiung-Mei Chen
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

Review 3.  Kynurenines in the mammalian brain: when physiology meets pathology.

Authors:  Robert Schwarcz; John P Bruno; Paul J Muchowski; Hui-Qiu Wu
Journal:  Nat Rev Neurosci       Date:  2012-07       Impact factor: 34.870

4.  Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India.

Authors:  Dhivya Venkatesan; Mahalaxmi Iyer; Robert Wilson S; Arul Narayanasamy; Siva Kamalakannan; Abilash Valsala Gopalakrishnan; Balachandar Vellingiri
Journal:  J Mol Neurosci       Date:  2022-06-08       Impact factor: 2.866

5.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

6.  Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain.

Authors:  G Ceresoli-Borroni; A Rassoulpour; H-Q Wu; P Guidetti; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

7.  Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity.

Authors:  B Poeggeler; A Rassoulpour; H-Q Wu; P Guidetti; R C Roberts; R Schwarcz
Journal:  Neuroscience       Date:  2007-07-16       Impact factor: 3.590

Review 8.  Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.

Authors:  Dániel Sandi; Zsanett Fricska-Nagy; Krisztina Bencsik; László Vécsei
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

9.  Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Arian Tavasol; Kimia Jazi; Ramtin Hajibeygi; Sina Shool; Fatemeh Sodeifian; Andis Klegeris; Alyssa McElhinney; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

10.  Chronic Antipsychotic Treatment in the Rat - Effects on Brain Interleukin-8 and Kynurenic Acid.

Authors:  Markus K Larsson; Lilly Schwieler; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Int J Tryptophan Res       Date:  2015-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.